New Drug News, In Brief
Executive Summary
FDA approves Abbott’s Humira for ulcerative colitis and Bayer/Onyx’s regorafenib for colorectal cancer, Bristol-Myers Squibb/Pfizer’s Eliquis faces a St. Patrick’s Day user fee date, and an NEJM poll finds the medical community is evenly split over use of Gilead’s Truvada for HIV pre-exposure prophylaxis.